Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients

Daniel Whittam; Alvaro Cobo-Calvo; a Sebastian Lopez-Chiriboga; Santiago Pardo; Matthew Gornall; Silvia Cicconi; Alexander Brandt; Klaus Berek; Thomas Berger; Ilijas Jelcic; Grace Gombolay; Luana Micheli Oliveira; Dagoberto Callegaro; Kimihiko Kaneko; Tatsuro Misu; Marco Capobianco; Emily Gibbons; Venkatraman Karthikeayan; Bruno Brochet; Bertrand Audoin; Guillaume Mathey; David Laplaud; Eric Thouvenot; Mikaël Cohen; Ayman Tourbah; Elisabeth Maillart; Jonathan Ciron; Romain Deschamps; Damien Biotti; Kevin Rostasy; Rinze Neuteboom; Cheryl Hemingway; Rob Forsyth; Marcelo Matiello; Stewart Webb; David Hunt; Katy Murray; Yael Hacohen; Ming Lim; M Isabel Leite; Jacqueline Palace; Tom Solomon; Andreas Lutterotti; Kazuo Fujihara; Ichiro Nakashima; Jeffrey Bennett; Lekha Pandit; Tanuja Chitnis; Brian Weinshenker; Brigitte Wildemann; Douglas Kazutoshi Sato; Su-Hyun Kim; Saif Huda; Ho Jin Kim; Markus Reindl; Michael Levy; Sven Jarius; Silvia Tenembaum; Friedemann Paul; Sean Pittock; Romain Marignier; Anu Jacob

doi:10.1016/j.msard.2020.102251

Article de revue

Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients

Daniel Whittam, Alvaro Cobo-Calvo, a Sebastian Lopez-Chiriboga, Santiago Pardo, Matthew Gornall, Silvia Cicconi, Alexander Brandt, Klaus Berek, Thomas Berger, Ilijas Jelcic, …

Multiple sclerosis and related disorders, Vol.44, pp.102251-102251

01/09/2020

DOI: https://doi.org/10.1016/j.msard.2020.102251

PMID: 32629363

Résumé

Human health and pathology

Life Sciences

Neurons and Cognition

Pediatrics

Sensory Organs

Objective: to assess the effect of anti-CD20 B-cell depletion with rituximab (RTX) on relapse rates in myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD).Methods: Retrospective review of RTX-treated MOGAD patients from 29 centres in 13 countries. The primary outcome measure was change in relapse rate after starting rituximab (Poisson regression model).Results: Data on 121 patients were analysed, including 30 (24.8%) children. Twenty/121 (16.5%) were treated after one attack, of whom 14/20 (70.0%) remained relapse-free after median (IQR) 11.2 (6.3-14.1) months. The remainder (101/121, 83.5%) were treated after two or more attacks, of whom 53/101 (52.5%) remained relapse-free after median 12.1 (6.3-24.9) months. In this 'relapsing group', relapse rate declined by 37% (95%CI=19-52%, p<0.001) overall, 63% (95%CI=35-79%, p = 0.001) when RTX was used first line (n = 47), and 26% (95%CI=2-44%, p = 0.038) when used after other steroid-sparing immunotherapies (n = 54). Predicted 1-year and 2-year relapse-free survival was 79% and 55% for first-line RTX therapy, and 38% and 18% for second-/third-line therapy. Circulating CD19+B-cells were suppressed to <1% of total circulating lymphocyte population at the time of 45/57 (78.9%) relapses.Conclusion: RTX reduced relapse rates in MOGAD. However, many patients continued to relapse despite apparent B-cell depletion. Prospective controlled studies are needed to validate these results.

Indicateurs

1 Consultations de la notice

See more details

Détails

Titre: Treatment of MOG-IgG-associated disorder with rituximab: an international study of 121 patients
Créateurs - sans rôle: Daniel Whittam - The Walton Centre NHS Foundation Trust
Alvaro Cobo-Calvo - Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL]
a Sebastian Lopez-Chiriboga - Mayo Clinic [Rochester]
Santiago Pardo - Massachusetts General Hospital [Boston]
Matthew Gornall - University of Liverpool
Silvia Cicconi - University of Liverpool
Alexander Brandt - Max Delbrueck Center for Molecular Medicine
Klaus Berek - Innsbruck Medical University = Medizinische Universität Innsbruck
Thomas Berger - Medical University of Vienna
Ilijas Jelcic - Universitätsspital Zürich
Grace Gombolay - Massachusetts General Hospital
Luana Micheli Oliveira - Hospital das Clinicas, University of Sao Paulo School of Medicine
Dagoberto Callegaro - Hospital das Clinicas, University of Sao Paulo School of Medicine
Kimihiko Kaneko - Tohoku University [Sendai]
Tatsuro Misu - Tohoku University [Sendai]
Marco Capobianco - Azienda Ospedaliera Universitaria San Luigi di Orbassano
Emily Gibbons - The Walton Centre NHS Foundation Trust
Venkatraman Karthikeayan - The Walton Centre NHS Foundation Trust
Bruno Brochet - Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale
Bertrand Audoin - Hôpital de la Timone [CHU - APHM]
Guillaume Mathey - Centre Hospitalier Régional Universitaire de Nancy
David Laplaud - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
Eric Thouvenot - Centre Hospitalier Universitaire de Nîmes
Mikaël Cohen - Centre Hospitalier Universitaire de Nice
Ayman Tourbah - Hôpital universitaire Robert Debré [Reims]
Elisabeth Maillart - CHU Pitié-Salpêtrière [AP-HP]
Jonathan Ciron - Centre hospitalier universitaire de Poitiers = Poitiers University Hospital
Romain Deschamps - Fondation Ophtalmologique Adolphe de Rothschild
Damien Biotti - Centre Hospitalier Universitaire de Toulouse
Kevin Rostasy - Universität Witten/Herdecke
Rinze Neuteboom - Erasmus MC
Cheryl Hemingway - Great Ormond Street Hospital for Children [London]
Rob Forsyth - Newcastle University [Newcastle]
Marcelo Matiello - Massachusetts General Hospital [Boston]
Stewart Webb - Queen Elizabeth University Hospital (Glasgow)
David Hunt - Anne Rowling Clinic [Edinburgh, UK]
Katy Murray - Anne Rowling Clinic [Edinburgh, UK]
Yael Hacohen - Great Ormond Street Hospital for Children [London]
Ming Lim - Tourettes Clinic-Evelina Childrens Hospital at Guys and St. Thomas', Kings Health Partners AHSC
M Isabel Leite - Nuffield Department of Clinical Neurosciences [Oxford]
Jacqueline Palace - Nuffield Department of Clinical Neurosciences [Oxford]
Tom Solomon - The Walton Centre NHS Foundation Trust
Andreas Lutterotti - Universitätsspital Zürich
Kazuo Fujihara - Tohoku University
Ichiro Nakashima - Tohoku University
Jeffrey Bennett - University of Colorado Anschutz Medical Campus [Aurora]
Lekha Pandit - Department of Pharmaceutics, NGSM Institute of Pharmaceutical Science, NITTE Deemed to be University, Mangalore 575018, India
Tanuja Chitnis - Massachusetts General Hospital [Boston]
Brian Weinshenker - Mayo Clinic [Rochester]
Brigitte Wildemann - Heidelberg University Hospital [Heidelberg]
Douglas Kazutoshi Sato - Hospital das Clinicas, University of Sao Paulo School of Medicine
Su-Hyun Kim - Hospital of National Cancer Center [Goyang]
Saif Huda - The Walton Centre NHS Foundation Trust
Ho Jin Kim - Hospital of National Cancer Center [Goyang]
Markus Reindl - Innsbruck Medical University = Medizinische Universität Innsbruck
Michael Levy - Massachusetts General Hospital [Boston]
Sven Jarius - Heidelberg University Hospital [Heidelberg]
Silvia Tenembaum - Hospital Nacional de Pediatría Prof. Dr Juan P. Garrahan [Buenos Aires]
Friedemann Paul - Max Delbrueck Center for Molecular Medicine
Sean Pittock - Mayo Clinic [Rochester]
Romain Marignier - Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL]
Anu Jacob - The Walton Centre NHS Foundation Trust
Détails de publication: Multiple sclerosis and related disorders, Vol.44, pp.102251-102251
Éditeur: Elsevier
Identifiants: 99139573709311
Unité académique: Institut de Génomique Fonctionnelle - IGF
Langue: English
Type de ressource: Journal article